
Aemetis Reports 2024 Fourth Quarter and Year-End Results
Annual Revenues Increased 43% to $268 million
India biodiesel annual revenues increased 20% to $93 million.
India biodiesel annual production capacity increased 33% from 60 mgy to 80 mgy.
California ethanol annual revenues increased 55% to $162 million.
Aemetis Biogas increased annual revenues by 139%.
Aemetis Biogas increased annual production capacity by 80%.
Solar and biogas dairy digester projects finished in 2024 resulted in cash proceeds of $19.4 million during Q1 2025 from the sale of investment tax credits.
CUPERTINO, CA - March 13, 2025 ( NEWMEDIAWIRE) - Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products, today announced its financial results for the fourth quarter and year ending December 31, 2024.
'Revenues for the full year of 2024 were $268 million, an increase of $81 million compared to 2023, driven by significant growth in every business segment,' said Todd Waltz, Chief Financial Officer of Aemetis. 'Capital expenditures for carbon intensity reduction and the expansion of biogas production capacity were $20.3 million for 2024 as our engineering and construction teams moved forward with low carbon initiatives that we expect to complete this year and next,' added Waltz.
Aemetis is pleased with the key achievements during 2024, reflecting our commitment to innovation, sustainability, and growth in the renewable energy sector. Notable milestones include:
Solar Microgrid Installation: Completed the installation of a $12 million, 1.9 MW solar microgrid with battery storage at our California ethanol plant, resulting in reductions in energy costs and the carbon intensity of our ethanol production.
California Low Carbon Fuel Standard (LCFS) Credits: Initiated the generation and sale of LCFS credits by our Renewable Natural Gas business.
Sustainable Aviation Fuel and Renewable Diesel Plant: Received the Authority to Construct air permits needed to develop a 90 million gallon per year sustainable aviation fuel and renewable diesel production facility at the Riverbank Industrial Complex.
IRA Section 48C Tax Credit Allocation: Received an allocation of $10.5 million in IRA Section 48C Tax Credits for the installation of a Mechanical Vapor Recompression system at our ethanol plant, in addition to $6 million in California Energy Commission grants and $3.2 million in PG&E grants.
India Business Expansion: Appointed a new CEO to lead growth initiatives for our India subsidiary, with a focus on advancing toward an initial public offering (IPO) for the India business.
Biodiesel Production Capacity: Increased biodiesel production capacity in India from 60 million gallons per year to 80 million gallons per year, further enhancing our global renewable energy footprint.
Biogas Production Increase: Completed construction of four new dairy digesters, which, along with seven already operating digesters and one digester nearing completion, are expected to have a production capacity of 550,000 MMBtu of renewable natural gas (RNG) per year.
These accomplishments demonstrate Aemetis' successful progress in advancing sustainable energy solutions and contributing towards a lower-carbon economy.
'In addition to achieving important operational milestones during 2024 in all of our business segments, we began generating valuable 45Z tax credits in January 2025, and E15 ethanol blends have already been approved by the EPA for eight states with approval for 49 states expected by the end of 2025,' said Eric McAfee, Chairman and CEO of Aemetis. 'Expanding domestic, lower cost energy that provides revenues to farmers and strengthens rural areas is the core of our mission at Aemetis, so we are pleased to see policy support from the White House and Congress for our growth plans.'
Today, Aemetis will host an earnings review call at 11:00 a.m. Pacific time (PT).
Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 194622
For the presentation and details on the call, please visit http://www.aemetis.com/investors/conference-calls/.
Financial Results for the Three Months Ended December 31, 2024
Revenues were $47.0 million for the fourth quarter of 2024, a decrease from $70.8 million for the fourth quarter of 2023. The ethanol and alcohol gallons sold were slightly higher at 15.7 million gallons during the fourth quarter of 2024 compared to 15.0 million gallons during the fourth quarter of 2024. Average selling price fell from $2.20 during the fourth quarter of 2023 to $1.93 during the fourth quarter of 2024, together impacting revenues by $4.2 million. Biodiesel sales fell from $22 million during the fourth quarter of 2023 to $3 million due to gap in the OMC tender offers during the fourth quarter of 2024.
Cost of Goods Sold decreased from $70 million during the fourth quarter of 2023 to $49 million during the fourth quarter of 2024, due to a gap in the OMC tender offers India Biodiesel segment.
Gross loss for the fourth quarter of 2024 was $2.0 million, compared to a gross profit of $864 thousand during the same period in 2023.
Selling, general and administrative expenses rose from $9.8 million during the fourth quarter of 2023 to $11.4 million during the fourth quarter of 2024.
Operating loss was $13.5 million for the fourth quarter of 2024, compared to an operating loss of $9.0 million during the fourth quarter of 2023.
Net loss was $16.2 million for the fourth quarter of 2024, compared to a net loss of $25.4 million for the fourth quarter of 2023.
Income tax benefit reflects the sale of $12.3 million of tax credits at the end of the fourth quarter of 2024.
Cash at the end of the fourth quarter of 2024 was $898 thousand, compared to $2.7 million at the end of the fourth quarter of 2023.
Financial Results for the Twelve Months Ended December 31, 2024
Revenues were $268 million for the twelve months ended December 31, 2024, compared to $187 million for 2023 with all three segments reporting increases, specifically, California Ethanol increased by $57.7 million from operating during the full year, India Biodiesel increased $15.7 million from stronger OMC tender delivery volumes, and California Renewable Natural Gas increased $7.6 million from increased production, stronger sales of RINs and sales of LCFS credits.
Cost of Goods Sold increased from $184.7 million during the twelve months ending December 31, 2023, to $268.2 million during the same period in 2024 in keeping with the change in revenues for each segment.
Gross loss for the twelve months ended December 31, 2024, was $580 thousand, compared to a gross profit of $2.0 million during the same period in 2023. Our Dairy Renewable Natural Gas segment accounted for $5.4 million of gross profit principally from sales of environmental attributes for the year ended December 31, 2024.
Selling, general and administrative expenses remained constant at $39.8 million during the twelve months ended December 31, 2024, compared to $39.4 million during the same period in 2023.
Operating loss was $40.4 million for the twelve months ending December 31, 2024, compared to an operating loss of $37.4 million for the same period in 2023.
Interest expense was $46.6 million during the year ending December 31, 2024, excluding accretion and other expenses of Series A preferred units in our Aemetis Biogas LLC subsidiary, compared to interest expense of $39.5 million during the year ended December 31, 2023. Additionally, our Aemetis Biogas LLC subsidiary recognized $12.7 million of accretion and debt extinguishment costs in connection with redemption liabilities on its preferred stock during the year ended December 31, 2024, a 50% reduction compared to $25.3 million during the same period in 2023.
Income tax benefit of $10.8 million during 2024 and $53.7 million during 2023 represent tax credit sales of $12.3 million and $55 million, respectively.
Net loss was $87.5 million for the twelve months ending December 31, 2024, compared to a net loss of $46.4 million during the same period in 2023.
Cash at the end of the fourth quarter of 2024 was $898 thousand compared to $2.7 million on December 31, 2023. Investments in our low carbon initiatives increased property, plant, and equipment by $20.3 million during the twelve months ending December 31, 2024.
About Aemetis
Headquartered in Cupertino, California, Aemetis is a renewable natural gas, renewable fuel and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace petroleum-based products and reduce greenhouse gas emissions. Founded in 2006, Aemetis is operating and actively expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California's Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates an 80 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India and Europe. Aemetis is developing the sustainable aviation fuel (SAF) and renewable diesel fuel biorefinery in California to utilize renewable hydrogen, hydroelectric power, and renewable oils to produce low carbon intensity renewable jet and diesel fuel. For additional information about Aemetis, please visit www.aemetis.com.
NON-GAAP FINANCIAL INFORMATION
We have provided non-GAAP measures as a supplement to financial results based on GAAP. A reconciliation of the non-GAAP measures to the most directly comparable GAAP measures is included in the accompanying supplemental data. Adjusted EBITDA is defined as net income/(loss) plus (to the extent deducted in calculating such net income) interest and amortization expense, gain on debt extinguishment, USDA cash grants, income tax expense or benefit, intangible and other amortization expense, accretion expense, depreciation expense, loss on asset disposal and share-based compensation expense.
Adjusted EBITDA is not calculated in accordance with GAAP and should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA is presented solely as a supplemental disclosure because management believes that it is a useful performance measure that is widely used within the industry in which we operate. In addition, management uses Adjusted EBITDA for reviewing financial results, for budgeting and planning purposes and as a non-GAAP liquidity measure. Adjusted EBITDA measures are not calculated in the same manner by all companies and, accordingly, may not be an appropriate measure for comparison between companies.
Safe Harbor Statement
This news release contains forward-looking statements, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this news release include, without limitation, statements relating to our five-year growth plan; trends in market conditions with respect to prices for inputs for our products versus prices for our products; our ability to fund, develop, build, maintain and operate digesters, facilities and pipelines for our Dairy Renewable Natural Gas segment; our ability to fund, develop and operate our Sustainable Aviation Fuel, Renewable Diesel, and Carbon Capture and Sequestration projects, including obtaining required permits; our ability to receive awarded grants by meeting all of the required conditions, including meeting the minimum contributions; our ability to fund, develop and operate our sustainable aviation fuel and renewable biodiesel projects; our intention to repurchase the Series A preferred units relating to our Aemetis Biogas subsidiary and the expected valuation premium thereof; and our ability to raise additional capital. Words or phrases such as 'anticipates,' 'may,' 'will,' 'should,' 'believes,' 'estimates,' 'expects,' 'intends,' 'plans,' 'predicts,' 'projects,' 'showing signs,' 'targets,' 'view,' 'will likely result,' 'will continue' or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, competition in the ethanol, biodiesel and other industries in which we operate, commodity market risks including those that may result from current weather conditions, financial market risks, customer adoption, counter-party risks, risks associated with changes to federal policy or regulation, and other risks detailed in our reports filed with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other filed documents. We are not obligated, and do not intend, to update any of these forward-looking statements at any time unless an update is required by applicable securities laws.
External Investor Relations Contact:
(646) 863-6519
[email protected]
Company Contact:
Todd Waltz
Chief Financial Officer
(408) 213-0925
(Tables follow)
AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
For the three months ended December 31, For the years ended December 31,
2024 2023 2024 2023
Revenues $ 47,004 $ 70,764 $ 267,640 $ 186,717
Cost of goods sold 49,044 69,900 268,220 184,700
Gross profit (loss) (2,040) 864 (580) 2,017
Selling, general and administrative expenses 11,436 9,823 39,836 39,418
Operating loss (13,476) (8,959) (40,416) (37,401)
Other expense (income):
Interest expense
Interest rate expense 11,066 8,869 40,158 32,995
Debt related fees and amortization expense 1,571 1,792 6,463 6,524
Accretion and other expenses of Series A preferred units 2,643 5,125 12,698 25,313
Other income (190) (57) (1,366) (2,077)
Loss before income taxes (28,566) (24,688) (98,369) (100,156)
Income tax expense (benefit) (12,369) 754 (10,832) (53,736)
Net loss $ (16,197) $ (25,442) $ (87,537) $ (46,420)
Net loss per common share
Basic $ (0.36) $ (0.64) $ (1.91) $ (1.22)
Diluted $ (0.36) $ (0.64) $ (1.91) $ (1.22)
Weighted average shares outstanding
Basic 45,612 39,674 45,902 38,061
Diluted 45,612 39,674 45,902 38,061
AEMETIS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands)
December 31,
2024 2023
Assets
Current assets:
Cash and cash equivalents $ 898 $ 2,667
Accounts receivable 1,805 8,633
Inventories 25,442 18,291
Tax credit sale receivable 12,300 -
Prepaid and other current assets 4,251 6,809
Total current assets 44,696 36,400
Property, plant and equipment, net 199,392 195,108
Other assets 15,214 11,898
Total assets $ 259,302 $ 243,406
Liabilities and stockholders' deficit
Current liabilities:
Accounts payable $ 33,139 $ 32,132
Current portion of long term debt 63,745 13,585
Short term borrowings 26,789 23,443
Other current liabilities 20,295 15,229
Total current liabilities 143,968 84,389
Total long term liabilities 379,262 375,994
Stockholders' deficit:
Common stock 51 41
Additional paid-in capital 305,329 264,058
Accumulated deficit (562,942) (475,405)
Accumulated other comprehensive loss (6,366) (5,671)
Total stockholders' deficit (263,928) (216,977)
Total liabilities and stockholders' deficit $ 259,302 $ 243,406
RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME / (LOSS)
(In thousands, unaudited)
For the three months ended
December 31,
For the years ended
December 31,
EBITDA Calculation 2024 2023 2024 2023
Net income (loss) $ (16,197) $ (25,442) $ (87,537) $ (46,420)
Adjustments
Interest and amortization expense 12,637 10,661 46,621 39,519
Depreciation expense 2,220 1,725 8,341 6,933
Accretion of Series A preferred units 2,643 5,125 12,698 25,313
Loss on asset disposal 58 - 3,702 -
Gain on debt extinguishment - - (162) -
Share-based compensation 1,386 1,437 8,314 7,660
Intangibles amortization expense 10 36 46 72
USDA cash grants - - - (1,774)
Income tax expense (benefit) (12,369) 754 (10,832) (53,736)
Total adjustments 6,585 19,738 68,728 23,987
Adjusted EBITDA $ (9,612) $ (5,704) $ (18,809) $ (22,433)
PRODUCTION AND PRICE PERFORMANCE
(unaudited)
Three Months ended
December 31,
Years ended
December 31,
2024 2023 2024 2023
California Ethanol
Ethanol
Gallons sold (in millions) 15.7 15.0 60.6 32.1
Average sales price/gallon $ 1.93 $ 2.20 $ 1.96 $ 2.44
Percent of nameplate capacity 114 % 109 % 110 % 58 %
WDG
Tons sold (in thousands) 105.7 102.6 410.6 225.3
Average sales price/ton $ 83 $ 97 $ 88 $ 97
Delivered Cost of Corn
Bushels ground (in millions) 5.4 5.2 21.0 11.5
Average delivered cost / bushel $ 6.08 $ 6.70 $ 6.21 $ 7.11
California Dairy Renewable Natural Gas
Renewable Natural Gas
MMBtu sold (in thousands) 67.1 52.2 301.9 194.2
Average price per MMBtu $ 3.45 $ 5.03 $ 3.01 $ 5.12
MMBtu available to dispense 24.6 68.0 24.6 68.0
RINs
RINs sold (in thousands) 987.3 1130.0 3,029.9 1400.7
Average price per RIN $ 2.7 $ 3.3 $ 3.0 $ 3.2
LCFS
LCFS credits sold (in thousands) 8.5 - 51.5 -
Average price per LCFS credit $ 64.8 $ - $ 56.7 $ -
India Biodiesel
Biodiesel
Metric tons sold (in thousands) 0.7 18.3 74.2 60.5
Average Sales Price/Metric ton $ 1,227 $ 1,157 $ 1,168 $ 1,232
Percent of Nameplate Capacity 1.8 % 49.0 % 49.5 % 40.0 %
Refined Glycerin
Metric tons sold (in thousands) 1.1 1.3 6.5 4.2
Average Sales Price/Metric ton $ 761 $ 616 $ 645 $ 640
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
GeoVax to Participate in BIO International Convention 2025
ATLANTA, GA - June 12, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced that company representatives will attend the 2025 BIO International Convention being held June 16-19, 2025 at the Boston Convention and Exhibition Center in Boston, Massachusetts. The BIO International Convention is the world's largest gathering of the biotechnology industry, attracting thousands of biotechnology and pharmaceutical executives from around the globe. The event provides an ideal venue for companies to engage with potential partners, investors, and policymakers. During the convention, GeoVax will participate in business development and partnering meetings to discuss its expanding pipeline of infectious disease and cancer immunotherapies, including GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting Mpox and smallpox; GEO-CM04S1, a multi-antigen COVID-19 vaccine candidate; and Gedeptin(R), a gene-directed enzyme prodrug therapy for the treatment of solid tumors. GeoVax's participation at BIO 2025 supports its broader business development strategy, including ongoing efforts to establish strategic partnerships, expand manufacturing capabilities, and align with public and private sector priorities in pandemic preparedness, oncology, and biodefense. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relationsgeovax@ Contact: Media Contact:Jessica Starmanmedia@ View the original release on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
5 hours ago
- Associated Press
New Book On Board Equips Corporate Boards to Navigate Governance in a Changing Business Climate
NEW YORK, NY - June 11, 2025 ( NEWMEDIAWIRE ) - Corporate governance faces increased scrutiny amid economic uncertainty and evolving expectations. Corporate board members and executives now have a unique resource: On Board: The Modern Playbook for Corporate Governance, by governance expert Jon Foster. This vital guide provides a readable historical perspective on how we got to now with a contemporary history of transactions (mergers and acquisitions, LBOs, activism, and restructurings), the growing importance of institutional investors, and the rise and now waning of environmental, social, and governance (ESG) issues that provide context for today's laws, standards, and best practices for good governance. Then, with experience, stories, and anecdotes from inside boardrooms, courtrooms, and investor meetings, Foster provides critical insights on the key issues that boards face. These include recruiting and onboarding directors, overseeing but not managing the company, board leadership, board committees, interacting effectively with the CEO, seeing that there are plans to mitigate risks and handle crises, and whether the board should target the maximization of shareholder or stakeholder value. This timely book, which addresses the dynamic landscape of governance and leadership, equips readers with the knowledge they need to navigate today's complex business environment. With experience on over 50 corporate boards, an expert witness on governance, mergers and acquisitions, restructurings and other topics in some 60 cases, and more than three decades as an investment banker, Foster offers informed views on board oversight, fiduciary responsibilities, management, shareholder engagement, and emerging governance challenges. This book provides a practical and straightforward approach to building and sustaining high-functioning boards that promote long-term success while managing risks and addressing shareholder expectations. 'As corporate governance evolves, it becomes increasingly critical for boards to clearly understand and address effectively their responsibilities and stay ahead of emerging trends,' Foster explains. 'On Board is a modern playbook for directors, offering actionable guidance rooted in lessons from the past, real-world experience, and anticipation of what may come next.' Key Themes in On Board: About Jonathan F. Foster is a deeply experienced corporate director, investment banker, and expert witness in corporate litigation. He has been on over 50 boards of directors of Fortune 500 companies, private equity firm portfolio companies, private companies, and distressed companies. He has served as a non-executive chairman, audit committee chair, and member of numerous board committees. Foster founded and is managing partner of Current Capital Partners, an advisory and merchant banking firm. Media Contact Full Name: Kathleen Schmidt Title: Founder Company Name: KMSPR Email: [email protected] Phone Number: 19734777091 Website:
Yahoo
14 hours ago
- Yahoo
New Book On Board Equips Corporate Boards to Navigate Governance in a Changing Business Climate
NEW YORK, NY - June 11, 2025 (NEWMEDIAWIRE) - Corporate governance faces increased scrutiny amid economic uncertainty and evolving expectations. Corporate board members and executives now have a unique resource: On Board: The Modern Playbook for Corporate Governance, by governance expert Jon Foster. This vital guide provides a readable historical perspective on how we got to now with a contemporary history of transactions (mergers and acquisitions, LBOs, activism, and restructurings), the growing importance of institutional investors, and the rise and now waning of environmental, social, and governance (ESG) issues that provide context for today's laws, standards, and best practices for good governance. Then, with experience, stories, and anecdotes from inside boardrooms, courtrooms, and investor meetings, Foster provides critical insights on the key issues that boards face. These include recruiting and onboarding directors, overseeing but not managing the company, board leadership, board committees, interacting effectively with the CEO, seeing that there are plans to mitigate risks and handle crises, and whether the board should target the maximization of shareholder or stakeholder value. This timely book, which addresses the dynamic landscape of governance and leadership, equips readers with the knowledge they need to navigate today's complex business environment. With experience on over 50 corporate boards, an expert witness on governance, mergers and acquisitions, restructurings and other topics in some 60 cases, and more than three decades as an investment banker, Foster offers informed views on board oversight, fiduciary responsibilities, management, shareholder engagement, and emerging governance challenges. This book provides a practical and straightforward approach to building and sustaining high-functioning boards that promote long-term success while managing risks and addressing shareholder expectations. "As corporate governance evolves, it becomes increasingly critical for boards to clearly understand and address effectively their responsibilities and stay ahead of emerging trends," Foster explains. "On Board is a modern playbook for directors, offering actionable guidance rooted in lessons from the past, real-world experience, and anticipation of what may come next." Key Themes in On Board: A Historical Perspective: A contemporary history of how we have come to today's laws, regulations, standards, and expectations for good governance. What Do Directors Do and How Do Directors Do It: Oversight and the duties of care and loyalty, board committees, and board leadership. In What Context Must a Director Work: Corporate transactions, institutional investors, and ESG. What Can Directors Do to Promote Long-Term Success? New directors, the CEO, risks and crises, keeping a board fresh and sharp, emerging issues, and ten recommendations for good governance. About Jonathan F. Foster is a deeply experienced corporate director, investment banker, and expert witness in corporate litigation. He has been on over 50 boards of directors of Fortune 500 companies, private equity firm portfolio companies, private companies, and distressed companies. He has served as a non-executive chairman, audit committee chair, and member of numerous board committees. Foster founded and is managing partner of Current Capital Partners, an advisory and merchant banking firm. Media ContactFull Name: Kathleen SchmidtTitle: FounderCompany Name: KMSPREmail: kathleen@ Number: 19734777091Website: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data